Breadcrumb
  1. Home
  2. 340B Drug Pricing Program
  3. Program Integrity
  4. FY 2018 Manufacturer Audit Results

FY 2018 Manufacturer Audit Results

Updated 5/23/19. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.

Results posted for 5 audits.
Manufacturer Sort descending Labeler Codes Reviewed State OPA Findings Sanction Corrective Action Status
Belcher Pharmaceuticals, LLC
Contact Information

General Counsel
Belcher Pharmaceuticals, LLC
O: (727) 471-0850, ext 789 F: (727) 471-0858
M: (813) 418-
9034
sst@belcherpharma.com
www.belcherpharma.com

62250 FL

Belcher did not offer covered outpatient drugs to eligible covered entities at the statutory ceiling price.

Repayment to covered entities

CAP implemented

Audit closure date: May 8, 2019

Cumberland Pharmaceuticals, Inc. 66220 TN

No adverse findings

None

N/A

Horizon Pharma USA, Inc. 75987
42238
49663
76325
IL

No adverse findings

None

N/A

Johnson & Johnson Health Care Systems 00045
00062
50458
08004
62341
10147
16837
17314
56091
57894
59676
65847
68669
NJ

No adverse findings

None

N/A

Takeda Pharmaceuticals America, Inc. 64764 IL

No adverse findings

None

N/A

Date Last Reviewed: